MX2018013981A - Improved peptide pharmaceuticals for insulin resistance. - Google Patents

Improved peptide pharmaceuticals for insulin resistance.

Info

Publication number
MX2018013981A
MX2018013981A MX2018013981A MX2018013981A MX2018013981A MX 2018013981 A MX2018013981 A MX 2018013981A MX 2018013981 A MX2018013981 A MX 2018013981A MX 2018013981 A MX2018013981 A MX 2018013981A MX 2018013981 A MX2018013981 A MX 2018013981A
Authority
MX
Mexico
Prior art keywords
insulin resistance
improved peptide
peptide pharmaceuticals
pharmaceuticals
modified peptides
Prior art date
Application number
MX2018013981A
Other languages
Spanish (es)
Inventor
John J Nestor
Original Assignee
Mederis Diabetes Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mederis Diabetes Llc filed Critical Mederis Diabetes Llc
Publication of MX2018013981A publication Critical patent/MX2018013981A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
MX2018013981A 2012-11-20 2015-05-20 Improved peptide pharmaceuticals for insulin resistance. MX2018013981A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261728649P 2012-11-20 2012-11-20

Publications (1)

Publication Number Publication Date
MX2018013981A true MX2018013981A (en) 2021-11-16

Family

ID=50776533

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006336A MX360816B (en) 2012-11-20 2013-11-20 Improved peptide pharmaceuticals for insulin resistance.
MX2018013981A MX2018013981A (en) 2012-11-20 2015-05-20 Improved peptide pharmaceuticals for insulin resistance.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015006336A MX360816B (en) 2012-11-20 2013-11-20 Improved peptide pharmaceuticals for insulin resistance.

Country Status (11)

Country Link
US (2) US11065304B2 (en)
EP (3) EP2922876B1 (en)
JP (1) JP6525456B2 (en)
KR (2) KR102213907B1 (en)
CN (1) CN104918961A (en)
AU (1) AU2013347975B2 (en)
BR (1) BR112015011478B1 (en)
CA (1) CA2891931A1 (en)
DK (1) DK2922876T3 (en)
MX (2) MX360816B (en)
WO (1) WO2014081872A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286400A2 (en) 2011-05-18 2023-12-06 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
MX344219B (en) * 2011-05-18 2016-12-07 Mederis Diabetes Llc Improved peptide pharmaceuticals for insulin resistance.
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
MX360816B (en) 2012-11-20 2018-11-15 Mederis Diabetes Llc Improved peptide pharmaceuticals for insulin resistance.
EP2922877B1 (en) 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9856306B2 (en) 2014-05-28 2018-01-02 Spitfire Pharma, Inc. Peptide pharmaceuticals for insulin resistance
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107636009B (en) 2014-12-30 2021-04-16 韩美药品株式会社 Glucagon derivatives with improved stability
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
NZ739250A (en) 2015-06-30 2024-02-23 Hanmi Pharm Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (en) * 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
NZ750267A (en) 2016-06-29 2023-12-22 Hanmi Pharm Ind Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
CN110545836A (en) 2017-01-24 2019-12-06 马克雷根有限公司 Treatment of age-related macular degeneration and other ocular diseases with apolipoprotein mimics
US20180296525A1 (en) 2017-03-03 2018-10-18 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
WO2019136158A1 (en) * 2018-01-03 2019-07-11 Spitfire Pharma, Inc. Improved peptide pharmaceuticals for treatment of nash and other disorders
BR112022016470A2 (en) * 2020-02-21 2022-11-22 Spitfire Pharma Llc PHARMACEUTICAL DOSAGE FORMULATION, AND, METHODS FOR LOWERING BLOOD GLUCOSE IN A MAMMAL AND FOR INDUCING WEIGHT LOSS IN A MAMMAL
CN113461747B (en) * 2021-07-12 2023-02-03 吉林化工学院 2 compounds with hypoglycemic activity in rose hip
WO2024026012A1 (en) * 2022-07-29 2024-02-01 The Regents Of The University Of California Compositions and methods for treating metabolic disorders

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (en) 1984-01-06 1987-04-21 Orion Yhtymae Oy ANTIBIOTIC EFFECT OF ERYTHROMYCIN COMPOUND AND PREPARATION CONTAINING THE COMPOUND
AT382381B (en) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz METHOD FOR PRODUCING NEW INTERFACE CHARACTERISTIC CARBOHYDRATE DERIVATIVES
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5661130A (en) * 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (en) 1997-08-15 1999-03-02 Asahi Glass Co Ltd Opioid peptide
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (en) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Muramic acid derivatives
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ES2606840T3 (en) 2001-10-10 2017-03-28 Ratiopharm Gmbh Remodeling and glycoconjugation of granulocyte colony stimulating factor (G-CSF)
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
AU2003220380A1 (en) 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US20110257096A1 (en) * 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ITRM20040607A1 (en) 2004-12-15 2005-03-15 Biogen S R L ANALOGUES OF THE DERMORFINA WITH ANALGESIC ACTIVITY.
WO2006096426A2 (en) 2005-03-03 2006-09-14 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
EP1767545B1 (en) * 2005-09-22 2009-11-11 Biocompatibles UK Limited GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
KR20150116465A (en) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
MX2010013454A (en) * 2008-06-17 2011-01-21 Tion Indiana University Res And Technology Corpora Glucagon/glp-1 receptor co-agonists.
ME02220B (en) 2009-07-13 2016-02-20 Zealand Pharma As Acylated glucagon analogues
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
JP2013517307A (en) * 2010-01-20 2013-05-16 ジーランド ファーマ アクティーゼルスカブ Heart disease treatment
US20130143798A1 (en) * 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
CN103458920B (en) * 2010-12-22 2016-07-06 印第安那大学科技研究公司 Show the glucagon analogs of GIP receptor active
KR101453037B1 (en) 2011-03-23 2014-10-21 주식회사 엘지화학 Electrode assembly for secondary battery preparation method of electrode assembly thereof
MX344219B (en) * 2011-05-18 2016-12-07 Mederis Diabetes Llc Improved peptide pharmaceuticals for insulin resistance.
EP4286400A2 (en) 2011-05-18 2023-12-06 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
JP2014011554A (en) 2012-06-28 2014-01-20 Seiichi Onoda Optical line monitoring method and optical line monitoring system
MX360816B (en) 2012-11-20 2018-11-15 Mederis Diabetes Llc Improved peptide pharmaceuticals for insulin resistance.
EP2922877B1 (en) 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
US9856306B2 (en) * 2014-05-28 2018-01-02 Spitfire Pharma, Inc. Peptide pharmaceuticals for insulin resistance
WO2019136158A1 (en) * 2018-01-03 2019-07-11 Spitfire Pharma, Inc. Improved peptide pharmaceuticals for treatment of nash and other disorders
BR112022016470A2 (en) * 2020-02-21 2022-11-22 Spitfire Pharma Llc PHARMACEUTICAL DOSAGE FORMULATION, AND, METHODS FOR LOWERING BLOOD GLUCOSE IN A MAMMAL AND FOR INDUCING WEIGHT LOSS IN A MAMMAL

Also Published As

Publication number Publication date
WO2014081872A1 (en) 2014-05-30
EP3434696A1 (en) 2019-01-30
EP2922876A4 (en) 2016-06-01
US20220362345A1 (en) 2022-11-17
DK2922876T3 (en) 2019-02-04
US11911447B2 (en) 2024-02-27
US20150290334A1 (en) 2015-10-15
BR112015011478A2 (en) 2017-08-15
KR20150088294A (en) 2015-07-31
EP2922876B1 (en) 2018-10-10
KR20210016083A (en) 2021-02-10
EP2922876A1 (en) 2015-09-30
EP3653649A1 (en) 2020-05-20
US11065304B2 (en) 2021-07-20
BR112015011478B1 (en) 2022-10-25
AU2013347975B2 (en) 2018-07-26
AU2013347975A1 (en) 2015-06-11
JP6525456B2 (en) 2019-06-05
JP2016501204A (en) 2016-01-18
KR102213907B1 (en) 2021-02-09
MX2015006336A (en) 2016-02-05
MX360816B (en) 2018-11-15
CN104918961A (en) 2015-09-16
CA2891931A1 (en) 2014-05-30
KR102365582B1 (en) 2022-02-18

Similar Documents

Publication Publication Date Title
MX2018013981A (en) Improved peptide pharmaceuticals for insulin resistance.
MX344219B (en) Improved peptide pharmaceuticals for insulin resistance.
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
MX2016015594A (en) Improved peptide pharmaceuticals for insulin resistance.
AU2019201173B2 (en) Novel polypeptides
SG11201403450VA (en) Artificial nucleic acid molecules for improved protein or peptide expression
TW201613958A (en) MIC-1 fusion proteins and uses thereof
WO2015037000A8 (en) Vstm5 polypeptides and uses thereof for treatment of cancer, infectious diseases and immune related diseases
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
IN2015DN02349A (en)
BR112014022788A2 (en) peptide, polypeptides, nucleic acid, pharmaceutical composition, conjugate and in vitro method
EP2651964A4 (en) Croos-linked peptides and proteins, methods of making same, and uses thereof
WO2014100481A3 (en) Modified alpha hemolysin polypeptides and methods of use
EP2935338A4 (en) Fusion protein of therapeutic polypeptide with improved pharmacokinetic profile and use thereof
MY166157A (en) Antibodies to bradykinin b1 receptor ligands
MX2014004953A (en) Tyrosine based linkers for the releasable connection of peptides.
IL235891A0 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EP3237374A4 (en) Amino acid and peptide conjugates and uses thereof
SG179200A1 (en) Fusion polypeptides and uses thereof
IL227737A0 (en) Drug delivery material capable of passing through blood-brain barrier, and peptide and use thereof
IN2014CN00510A (en)
EP3065783A4 (en) Dual molecular delivery of oligonucleotides and peptide containing conjugates
EP3419962A4 (en) Amino acid and peptide conjugates and conjugation process
WO2015057820A3 (en) Peptide constructs and well-defined aggregates thereof